{"entities":{"Q100596":{"pageid":90989,"ns":120,"title":"Item:Q100596","lastrevid":574132,"modified":"2026-08-16T17:19:26Z","type":"item","id":"Q100596","labels":{"mul":{"language":"mul","value":"ID_351394127"},"pt-br":{"language":"pt-br","value":"Degenera\u00e7\u00e3o cerebelar paraneopl\u00e1sica, autoanticorpo neuronal positivo"},"en":{"language":"en","value":"Paraneoplastic cerebellar degeneration, neural autoantibody positive"}},"descriptions":{"pt-br":{"language":"pt-br","value":"Degenera\u00e7\u00e3o cerebelar paraneopl\u00e1sica soropositiva para autoanticorpos neurais. Quando esses anticorpos neurais t\u00eam como alvo ant\u00edgenos da membrana plasm\u00e1tica, eles s\u00e3o efetores de les\u00e3o (por exemplo, autoanticorpos complexos de canais de pot\u00e1ssio controlados por voltagem) por meio de m\u00faltiplos mecanismos efetores. No entanto, ao alvejar ant\u00edgenos nucleares ou citoplasm\u00e1ticos (por exemplo, autoanticorpo de c\u00e9lula de Purkinje tipo 1 [PCA-1 ou anti-Yo] mais frequentemente associado a tumores ovarianos), eles s\u00e3o marcadores de uma les\u00e3o mediada por efetores de c\u00e9lulas T, pois s\u00e3o inacess\u00edveis ao ataque imunol\u00f3gico em situ, mas os pept\u00eddeos de prote\u00ednas intracelulares s\u00e3o exibidos em mol\u00e9culas de MHC de classe 1 reguladas positivamente em um meio de citocinas pr\u00f3-inflamat\u00f3rias e, em seguida, acess\u00edveis a c\u00e9lulas T citot\u00f3xicas espec\u00edficas de pept\u00eddeo._x000D_ _x000D_ Os autoanticorpos neurais associados incluem:_x000D_ _x000D_ ANNA-2 (anti-Ri) (autoanticorpo nuclear antineuronal tipo 2); CRMP5 (anti-CV2) (prote\u00edna 5 do mediador da resposta da colapsina); mGluR1 (anticorpo metabotr\u00f3pico para o receptor de glutamato tipo 1); GABABR (autoanticorpos do tipo B de \u00e1cido gama-aminobut\u00edrico); Ma1; Ma2; PCA-1 (anti-Yo) (autoanticorpo citoplasm\u00e1tico de c\u00e9lulas de purkinje tipo 1); PCA-2 (autoanticorpo citoplasm\u00e1tico de c\u00e9lulas de purkinje tipo 2); PCA-Tr (autoanticorpo de c\u00e9lulas purkinje-Tr);"},"en":{"language":"en","value":"Paraneoplastic cerebellar degeneration seropositive for neural autoantibodies. When these neural antibodies target plasma membrane antigens they are effectors of injury (e.g. voltage gated potassium channel complex autoantibodies) through multiple effector mechanisms. However, when targeting nuclear or cytoplasmic antigens (e.g. Purkinje cell autoantibody type 1 [PCA-1 or anti-Yo] most frequently associated with ovarian tumours) they are markers of a T-cell effector mediated injury as they are inaccessible to immune attack in situ, but peptides from intracellular proteins are displayed on upregulated MHC class 1 molecules in a pro-inflammatory cytokine milieu and then accessible to peptide specific cytotoxic T-cells.  Associated neural autoantibodies include: ANNA-2(anti-Ri) (antineuronal nuclear autoantibody type 2); CRMP5(anti-CV2) (collapsin response mediator protein 5); mGluR1 (metabotropic glutamate receptor antibody type 1); GABABR (Gamma-aminobutyric-acid type-B autoantibodies); Ma1; Ma2; PCA-1(anti-Yo) (purkinje cell cytoplasmic autoantibody type 1); PCA-2 (purkinje cell cytoplasmic autoantibody type 2); PCA-Tr (purkinje cell autoantibody-Tr);"}},"aliases":{},"claims":{"P68":[{"mainsnak":{"snaktype":"value","property":"P68","hash":"13a62145ddd39946cfd3b105a03bfb0079fbbf17","datavalue":{"value":"https://id.who.int/icd/entity/351394127","type":"string"},"datatype":"url"},"type":"statement","id":"Q100596$26C1D9EF-3F8A-4FD5-B902-C75E51513F92","rank":"normal"}],"P67":[{"mainsnak":{"snaktype":"value","property":"P67","hash":"33e1dbd23a6ebd45e51084bf973c7e8f9832d4c3","datavalue":{"value":"CID11:ID_351394127","type":"string"},"datatype":"string"},"type":"statement","id":"Q100596$C188D3C5-89D1-4E58-88AF-9B74D36754D7","rank":"normal"}],"P70":[{"mainsnak":{"snaktype":"value","property":"P70","hash":"f279ac332c614aafcb5d149b9807ad6dbc024c2e","datavalue":{"value":"dki-india-ID_351394127","type":"string"},"datatype":"string"},"type":"statement","id":"Q100596$45FD12FB-E1C3-4BA8-9D99-982D66DFA4FB","rank":"normal"}],"P86":[{"mainsnak":{"snaktype":"value","property":"P86","hash":"a96031634b9f5dafddaf781bbba3adea6bb64ef4","datavalue":{"value":"Conclu\u00eddo","type":"string"},"datatype":"string"},"type":"statement","id":"Q100596$9FF63BB1-AF84-451A-90BB-8B098516E07A","rank":"normal"}],"P78":[{"mainsnak":{"snaktype":"value","property":"P78","hash":"5f9b5be68b7400da549761cf15abfdbc4d1e075b","datavalue":{"value":"https://pauloleads.com.br/cases-publicos/","type":"string"},"datatype":"url"},"type":"statement","id":"Q100596$71169B2D-990E-468F-9200-D89DD1875859","rank":"normal"}],"P80":[{"mainsnak":{"snaktype":"value","property":"P80","hash":"378ac503ed43f21e1f461d2823a6ad59da580514","datavalue":{"value":{"time":"+2026-08-15T00:00:00Z","timezone":0,"before":0,"after":0,"precision":11,"calendarmodel":"http://www.wikidata.org/entity/Q1985727"},"type":"time"},"datatype":"time"},"type":"statement","id":"Q100596$6D8CEF15-B843-4B1C-A6C3-6CB9DC332DD5","rank":"normal"}]},"sitelinks":{}}}}